For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...

In 2011, Ashley Mauldin moved from a city with more than 165,000 residents to one with fewer than 5,000. Relocating from Fort Collins to New Castle proved stressful on its own, but Mauldin — just 27 ...

Shares of Relmada Therapeutics Inc. (NASDAQ:RLMD) were trading $2.15, down $2.01, or 48.3% on word of negative top-line results from the phase III study called Reliance-1, testing REL-1017 ...

Following a negative phase II/III study of an investigational treatment for major depressive disorder, Praxis Precision Medicines Inc. is dropping staff from the payroll and refocusing the company’s ...

A surprising new approach to depression treatment is showing early promise — not by targeting brain chemicals, but by calming the immune system. In a small clinical trial, researchers found that an ...

Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for ...